Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Disease-Modifying Agents Market by Drug Class (Interferon Beta-1?/?, Natalizumab, Mitoxantrone, Glatiramer Acetate, Fingolimod, Dimethyl Fumarate, Ocrelizumab, Teriflunomide, Ciclosporin, Cyclophosphamide, Hydroxychloroquine, Leflunomide, Methotrexate, Mycophenolate, Sulfasalazine, Others), by Indication (Multiple Sclerosis, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Systemic Sclerosis, Cancer, Others), by Therapy Type (Monotherapy, Combination therapy), by Route of Administration (Oral, Infusion, Subcutaneous, Intravenous) and by End User (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

A12016

Pages: NA

Charts: NA

Tables: NA

Disease modification can be defined as treatments that affect the underlying pathophysiology of the disease and have a beneficial outcome. In the struggle to decrease the development of disease in many inflammatory conditions such as rheumatoid arthritis, psoriasis, and psoriatic arthritis, multiple sclerosis, and Crohn's disease, the disease-modifying agent class, including treatments such as anti-TNF agents and immunomodulators, averting the progression of each disease and also the market is experiencing notable growth. However, the landscape has changed with the entry of disease-modifying agents. Several new disease-modifying drugs are in the line, all of which will offer important options for patients with these diseases, thus promoting the growth of the disease-modifying agents market.

COVID-19 Impact analysis

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the disease-modifying agents market.

Top Impacting Factors

  • Increase in cases of inflammatory diseases, surge in geriatric population, rise in demand for minimally invasive procedure & advanced treatments such as disease modifying agents are the factors that drive the growth of the disease modifying agents market.
  • Disease-modifying anti-rheumatic agents work to suppress the body's overactive immune and/or inflammatory systems; anti-TNFs are extremely effective treatments; disease-modifying agents are also effective for osteoarthritis; however, the agents are still under the clinical trial phase. Limited availability of products is anticipated to provide a lucrative opportunity to launch disease-modifying agents in the market.
  • Few factors expected to hinder the growth of the disease modifying agents market include drug recalls by the FDA and EMA and increase in cost of multiple sclerosis disease-modifying agents.

Market Trends

Promising Product Pipeline Expected to Flourish the Market

Companies are taking efforts to develop therapeutic modalities for underlying pathophysiological changes in Alzheimer’s disease and other neurodegenerative disorders.

A phase 3 study of isradipine is being carried out as a disease-modifying agent in patients with early Parkinson's disease by STEADY-PD III, funded by National Institute of Neurological Disorders and Stroke (NINDS).

In September 2020, Prothena Corporation plc declared the results of the Phase 2 PASADENA study of prasinezumab, which is the first anti-inflammatory, anti-alpha-synuclein antibody to show efficacy in patients with early Parkinson's disease.

Key Benefits of the Report

  • This study presents the analytical depiction of the disease-modifying agents industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the disease-modifying agents market share.
  • The current market is quantitatively analyzed to highlight the disease-modifying agents market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed disease-modifying agents market analysis based on competitive intensity and how the competition will take shape in coming years

Questions answered in the disease-modifying agents Report

  • Who are the leading players active in the gamete preservation market?
  • What are the current trends that will influence the market in the next few years?
  • What is "Disease-modifying agents "?
  • What is "Disease-modifying agents" Market prediction in the future?
  • Who are the leading global players in the "Disease-modifying agents" Market?                                                                                                                                                                                                         

 Key Market Segments

  • By Drug Class
    • Interferon Beta-1α/β
    • Natalizumab
    • Mitoxantrone
    • Glatiramer Acetate
    • Fingolimod
    • Dimethyl Fumarate
    • Ocrelizumab
    • Teriflunomide
    • Ciclosporin
    • Cyclophosphamide
    • Hydroxychloroquine
    • Leflunomide
    • Methotrexate
    • Mycophenolate
    • Sulfasalazine
    • Others
  • By Indication
    • Multiple Sclerosis
    • Rheumatoid Arthritis
    • Psoriatic Arthritis
    • Ankylosing Spondylitis
    • Systemic Sclerosis
    • Cancer
    • Others
  • By Therapy Type
    • Monotherapy
    • Combination therapy
  • By Route of Administration
    • Oral
    • Infusion
    • Subcutaneous
    • Intravenous
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA
  • By End User
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Others

 
Key Market Players

  • Biogen Inc.
  • Nordic Group Bv
  • Accord Healthcare Inc
  • Fresenius Kabi
  • Antares Pharma, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Elan Pharma India Pvt Ltd.
  • Merck KGaA
  • Pfizer Inc
  • Hospira, Inc.

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: DISEASE-MODIFYING AGENTS MARKET, BY DRUG CLASS

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Drug Class

    • 4.2. Interferon Beta-1α/β

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Natalizumab

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Mitoxantrone

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Glatiramer Acetate

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Fingolimod

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

    • 4.7. Dimethyl Fumarate

      • 4.7.1. Key Market Trends, Growth Factors and Opportunities

      • 4.7.2. Market Size and Forecast, By Region

      • 4.7.3. Market Share Analysis, By Country

    • 4.8. Ocrelizumab

      • 4.8.1. Key Market Trends, Growth Factors and Opportunities

      • 4.8.2. Market Size and Forecast, By Region

      • 4.8.3. Market Share Analysis, By Country

    • 4.9. Teriflunomide

      • 4.9.1. Key Market Trends, Growth Factors and Opportunities

      • 4.9.2. Market Size and Forecast, By Region

      • 4.9.3. Market Share Analysis, By Country

    • 4.10. Ciclosporin

      • 4.10.1. Key Market Trends, Growth Factors and Opportunities

      • 4.10.2. Market Size and Forecast, By Region

      • 4.10.3. Market Share Analysis, By Country

    • 4.11. Cyclophosphamide

      • 4.11.1. Key Market Trends, Growth Factors and Opportunities

      • 4.11.2. Market Size and Forecast, By Region

      • 4.11.3. Market Share Analysis, By Country

    • 4.12. Hydroxychloroquine

      • 4.12.1. Key Market Trends, Growth Factors and Opportunities

      • 4.12.2. Market Size and Forecast, By Region

      • 4.12.3. Market Share Analysis, By Country

    • 4.13. Leflunomide

      • 4.13.1. Key Market Trends, Growth Factors and Opportunities

      • 4.13.2. Market Size and Forecast, By Region

      • 4.13.3. Market Share Analysis, By Country

    • 4.14. Methotrexate

      • 4.14.1. Key Market Trends, Growth Factors and Opportunities

      • 4.14.2. Market Size and Forecast, By Region

      • 4.14.3. Market Share Analysis, By Country

    • 4.15. Mycophenolate

      • 4.15.1. Key Market Trends, Growth Factors and Opportunities

      • 4.15.2. Market Size and Forecast, By Region

      • 4.15.3. Market Share Analysis, By Country

    • 4.16. Sulfasalazine

      • 4.16.1. Key Market Trends, Growth Factors and Opportunities

      • 4.16.2. Market Size and Forecast, By Region

      • 4.16.3. Market Share Analysis, By Country

    • 4.17. Others

      • 4.17.1. Key Market Trends, Growth Factors and Opportunities

      • 4.17.2. Market Size and Forecast, By Region

      • 4.17.3. Market Share Analysis, By Country

  • CHAPTER 5: DISEASE-MODIFYING AGENTS MARKET, BY INDICATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Indication

    • 5.2. Multiple Sclerosis

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Rheumatoid Arthritis

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Psoriatic Arthritis

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Ankylosing Spondylitis

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

    • 5.6. Systemic Sclerosis

      • 5.6.1. Key Market Trends, Growth Factors and Opportunities

      • 5.6.2. Market Size and Forecast, By Region

      • 5.6.3. Market Share Analysis, By Country

    • 5.7. Cancer

      • 5.7.1. Key Market Trends, Growth Factors and Opportunities

      • 5.7.2. Market Size and Forecast, By Region

      • 5.7.3. Market Share Analysis, By Country

    • 5.8. Others

      • 5.8.1. Key Market Trends, Growth Factors and Opportunities

      • 5.8.2. Market Size and Forecast, By Region

      • 5.8.3. Market Share Analysis, By Country

  • CHAPTER 6: DISEASE-MODIFYING AGENTS MARKET, BY THERAPY TYPE

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Therapy Type

    • 6.2. Monotherapy

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Combination Therapy

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

  • CHAPTER 7: DISEASE-MODIFYING AGENTS MARKET, BY ROUTE OF ADMINISTRATION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Route Of Administration

    • 7.2. Oral

      • 7.2.1. Key Market Trends, Growth Factors and Opportunities

      • 7.2.2. Market Size and Forecast, By Region

      • 7.2.3. Market Share Analysis, By Country

    • 7.3. Infusion

      • 7.3.1. Key Market Trends, Growth Factors and Opportunities

      • 7.3.2. Market Size and Forecast, By Region

      • 7.3.3. Market Share Analysis, By Country

    • 7.4. Subcutaneous

      • 7.4.1. Key Market Trends, Growth Factors and Opportunities

      • 7.4.2. Market Size and Forecast, By Region

      • 7.4.3. Market Share Analysis, By Country

    • 7.5. Intravenous

      • 7.5.1. Key Market Trends, Growth Factors and Opportunities

      • 7.5.2. Market Size and Forecast, By Region

      • 7.5.3. Market Share Analysis, By Country

  • CHAPTER 8: DISEASE-MODIFYING AGENTS MARKET, BY END USER

    • 8.1. Market Overview

      • 8.1.1 Market Size and Forecast, By End User

    • 8.2. Hospital Pharmacies

      • 8.2.1. Key Market Trends, Growth Factors and Opportunities

      • 8.2.2. Market Size and Forecast, By Region

      • 8.2.3. Market Share Analysis, By Country

    • 8.3. Retail Pharmacies

      • 8.3.1. Key Market Trends, Growth Factors and Opportunities

      • 8.3.2. Market Size and Forecast, By Region

      • 8.3.3. Market Share Analysis, By Country

    • 8.4. Online Pharmacies

      • 8.4.1. Key Market Trends, Growth Factors and Opportunities

      • 8.4.2. Market Size and Forecast, By Region

      • 8.4.3. Market Share Analysis, By Country

    • 8.5. Others

      • 8.5.1. Key Market Trends, Growth Factors and Opportunities

      • 8.5.2. Market Size and Forecast, By Region

      • 8.5.3. Market Share Analysis, By Country

  • CHAPTER 9: DISEASE-MODIFYING AGENTS MARKET, BY REGION

    • 9.1. Market Overview

      • 9.1.1 Market Size and Forecast, By Region

    • 9.2. North America

      • 9.2.1. Key Market Trends and Opportunities

      • 9.2.2. Market Size and Forecast, By Drug Class

      • 9.2.3. Market Size and Forecast, By Indication

      • 9.2.4. Market Size and Forecast, By Therapy Type

      • 9.2.5. Market Size and Forecast, By Route Of Administration

      • 9.2.6. Market Size and Forecast, By End User

      • 9.2.7. Market Size and Forecast, By Country

      • 9.2.8. U.S. Disease-modifying Agents Market

        • 9.2.8.1. Market Size and Forecast, By Drug Class
        • 9.2.8.2. Market Size and Forecast, By Indication
        • 9.2.8.3. Market Size and Forecast, By Therapy Type
        • 9.2.8.4. Market Size and Forecast, By Route Of Administration
        • 9.2.8.5. Market Size and Forecast, By End User

      • 9.2.9. Canada Disease-modifying Agents Market

        • 9.2.9.1. Market Size and Forecast, By Drug Class
        • 9.2.9.2. Market Size and Forecast, By Indication
        • 9.2.9.3. Market Size and Forecast, By Therapy Type
        • 9.2.9.4. Market Size and Forecast, By Route Of Administration
        • 9.2.9.5. Market Size and Forecast, By End User

      • 9.2.10. Mexico Disease-modifying Agents Market

        • 9.2.10.1. Market Size and Forecast, By Drug Class
        • 9.2.10.2. Market Size and Forecast, By Indication
        • 9.2.10.3. Market Size and Forecast, By Therapy Type
        • 9.2.10.4. Market Size and Forecast, By Route Of Administration
        • 9.2.10.5. Market Size and Forecast, By End User

    • 9.3. Europe

      • 9.3.1. Key Market Trends and Opportunities

      • 9.3.2. Market Size and Forecast, By Drug Class

      • 9.3.3. Market Size and Forecast, By Indication

      • 9.3.4. Market Size and Forecast, By Therapy Type

      • 9.3.5. Market Size and Forecast, By Route Of Administration

      • 9.3.6. Market Size and Forecast, By End User

      • 9.3.7. Market Size and Forecast, By Country

      • 9.3.8. France Disease-modifying Agents Market

        • 9.3.8.1. Market Size and Forecast, By Drug Class
        • 9.3.8.2. Market Size and Forecast, By Indication
        • 9.3.8.3. Market Size and Forecast, By Therapy Type
        • 9.3.8.4. Market Size and Forecast, By Route Of Administration
        • 9.3.8.5. Market Size and Forecast, By End User

      • 9.3.9. Germany Disease-modifying Agents Market

        • 9.3.9.1. Market Size and Forecast, By Drug Class
        • 9.3.9.2. Market Size and Forecast, By Indication
        • 9.3.9.3. Market Size and Forecast, By Therapy Type
        • 9.3.9.4. Market Size and Forecast, By Route Of Administration
        • 9.3.9.5. Market Size and Forecast, By End User

      • 9.3.10. Italy Disease-modifying Agents Market

        • 9.3.10.1. Market Size and Forecast, By Drug Class
        • 9.3.10.2. Market Size and Forecast, By Indication
        • 9.3.10.3. Market Size and Forecast, By Therapy Type
        • 9.3.10.4. Market Size and Forecast, By Route Of Administration
        • 9.3.10.5. Market Size and Forecast, By End User

      • 9.3.11. Spain Disease-modifying Agents Market

        • 9.3.11.1. Market Size and Forecast, By Drug Class
        • 9.3.11.2. Market Size and Forecast, By Indication
        • 9.3.11.3. Market Size and Forecast, By Therapy Type
        • 9.3.11.4. Market Size and Forecast, By Route Of Administration
        • 9.3.11.5. Market Size and Forecast, By End User

      • 9.3.12. UK Disease-modifying Agents Market

        • 9.3.12.1. Market Size and Forecast, By Drug Class
        • 9.3.12.2. Market Size and Forecast, By Indication
        • 9.3.12.3. Market Size and Forecast, By Therapy Type
        • 9.3.12.4. Market Size and Forecast, By Route Of Administration
        • 9.3.12.5. Market Size and Forecast, By End User

      • 9.3.13. Russia Disease-modifying Agents Market

        • 9.3.13.1. Market Size and Forecast, By Drug Class
        • 9.3.13.2. Market Size and Forecast, By Indication
        • 9.3.13.3. Market Size and Forecast, By Therapy Type
        • 9.3.13.4. Market Size and Forecast, By Route Of Administration
        • 9.3.13.5. Market Size and Forecast, By End User

      • 9.3.14. Rest Of Europe Disease-modifying Agents Market

        • 9.3.14.1. Market Size and Forecast, By Drug Class
        • 9.3.14.2. Market Size and Forecast, By Indication
        • 9.3.14.3. Market Size and Forecast, By Therapy Type
        • 9.3.14.4. Market Size and Forecast, By Route Of Administration
        • 9.3.14.5. Market Size and Forecast, By End User

    • 9.4. Asia-Pacific

      • 9.4.1. Key Market Trends and Opportunities

      • 9.4.2. Market Size and Forecast, By Drug Class

      • 9.4.3. Market Size and Forecast, By Indication

      • 9.4.4. Market Size and Forecast, By Therapy Type

      • 9.4.5. Market Size and Forecast, By Route Of Administration

      • 9.4.6. Market Size and Forecast, By End User

      • 9.4.7. Market Size and Forecast, By Country

      • 9.4.8. China Disease-modifying Agents Market

        • 9.4.8.1. Market Size and Forecast, By Drug Class
        • 9.4.8.2. Market Size and Forecast, By Indication
        • 9.4.8.3. Market Size and Forecast, By Therapy Type
        • 9.4.8.4. Market Size and Forecast, By Route Of Administration
        • 9.4.8.5. Market Size and Forecast, By End User

      • 9.4.9. Japan Disease-modifying Agents Market

        • 9.4.9.1. Market Size and Forecast, By Drug Class
        • 9.4.9.2. Market Size and Forecast, By Indication
        • 9.4.9.3. Market Size and Forecast, By Therapy Type
        • 9.4.9.4. Market Size and Forecast, By Route Of Administration
        • 9.4.9.5. Market Size and Forecast, By End User

      • 9.4.10. India Disease-modifying Agents Market

        • 9.4.10.1. Market Size and Forecast, By Drug Class
        • 9.4.10.2. Market Size and Forecast, By Indication
        • 9.4.10.3. Market Size and Forecast, By Therapy Type
        • 9.4.10.4. Market Size and Forecast, By Route Of Administration
        • 9.4.10.5. Market Size and Forecast, By End User

      • 9.4.11. South Korea Disease-modifying Agents Market

        • 9.4.11.1. Market Size and Forecast, By Drug Class
        • 9.4.11.2. Market Size and Forecast, By Indication
        • 9.4.11.3. Market Size and Forecast, By Therapy Type
        • 9.4.11.4. Market Size and Forecast, By Route Of Administration
        • 9.4.11.5. Market Size and Forecast, By End User

      • 9.4.12. Australia Disease-modifying Agents Market

        • 9.4.12.1. Market Size and Forecast, By Drug Class
        • 9.4.12.2. Market Size and Forecast, By Indication
        • 9.4.12.3. Market Size and Forecast, By Therapy Type
        • 9.4.12.4. Market Size and Forecast, By Route Of Administration
        • 9.4.12.5. Market Size and Forecast, By End User

      • 9.4.13. Thailand Disease-modifying Agents Market

        • 9.4.13.1. Market Size and Forecast, By Drug Class
        • 9.4.13.2. Market Size and Forecast, By Indication
        • 9.4.13.3. Market Size and Forecast, By Therapy Type
        • 9.4.13.4. Market Size and Forecast, By Route Of Administration
        • 9.4.13.5. Market Size and Forecast, By End User

      • 9.4.14. Malaysia Disease-modifying Agents Market

        • 9.4.14.1. Market Size and Forecast, By Drug Class
        • 9.4.14.2. Market Size and Forecast, By Indication
        • 9.4.14.3. Market Size and Forecast, By Therapy Type
        • 9.4.14.4. Market Size and Forecast, By Route Of Administration
        • 9.4.14.5. Market Size and Forecast, By End User

      • 9.4.15. Indonesia Disease-modifying Agents Market

        • 9.4.15.1. Market Size and Forecast, By Drug Class
        • 9.4.15.2. Market Size and Forecast, By Indication
        • 9.4.15.3. Market Size and Forecast, By Therapy Type
        • 9.4.15.4. Market Size and Forecast, By Route Of Administration
        • 9.4.15.5. Market Size and Forecast, By End User

      • 9.4.16. Rest of Asia Pacific Disease-modifying Agents Market

        • 9.4.16.1. Market Size and Forecast, By Drug Class
        • 9.4.16.2. Market Size and Forecast, By Indication
        • 9.4.16.3. Market Size and Forecast, By Therapy Type
        • 9.4.16.4. Market Size and Forecast, By Route Of Administration
        • 9.4.16.5. Market Size and Forecast, By End User

    • 9.5. LAMEA

      • 9.5.1. Key Market Trends and Opportunities

      • 9.5.2. Market Size and Forecast, By Drug Class

      • 9.5.3. Market Size and Forecast, By Indication

      • 9.5.4. Market Size and Forecast, By Therapy Type

      • 9.5.5. Market Size and Forecast, By Route Of Administration

      • 9.5.6. Market Size and Forecast, By End User

      • 9.5.7. Market Size and Forecast, By Country

      • 9.5.8. Brazil Disease-modifying Agents Market

        • 9.5.8.1. Market Size and Forecast, By Drug Class
        • 9.5.8.2. Market Size and Forecast, By Indication
        • 9.5.8.3. Market Size and Forecast, By Therapy Type
        • 9.5.8.4. Market Size and Forecast, By Route Of Administration
        • 9.5.8.5. Market Size and Forecast, By End User

      • 9.5.9. South Africa Disease-modifying Agents Market

        • 9.5.9.1. Market Size and Forecast, By Drug Class
        • 9.5.9.2. Market Size and Forecast, By Indication
        • 9.5.9.3. Market Size and Forecast, By Therapy Type
        • 9.5.9.4. Market Size and Forecast, By Route Of Administration
        • 9.5.9.5. Market Size and Forecast, By End User

      • 9.5.10. Saudi Arabia Disease-modifying Agents Market

        • 9.5.10.1. Market Size and Forecast, By Drug Class
        • 9.5.10.2. Market Size and Forecast, By Indication
        • 9.5.10.3. Market Size and Forecast, By Therapy Type
        • 9.5.10.4. Market Size and Forecast, By Route Of Administration
        • 9.5.10.5. Market Size and Forecast, By End User

      • 9.5.11. UAE Disease-modifying Agents Market

        • 9.5.11.1. Market Size and Forecast, By Drug Class
        • 9.5.11.2. Market Size and Forecast, By Indication
        • 9.5.11.3. Market Size and Forecast, By Therapy Type
        • 9.5.11.4. Market Size and Forecast, By Route Of Administration
        • 9.5.11.5. Market Size and Forecast, By End User

      • 9.5.12. Argentina Disease-modifying Agents Market

        • 9.5.12.1. Market Size and Forecast, By Drug Class
        • 9.5.12.2. Market Size and Forecast, By Indication
        • 9.5.12.3. Market Size and Forecast, By Therapy Type
        • 9.5.12.4. Market Size and Forecast, By Route Of Administration
        • 9.5.12.5. Market Size and Forecast, By End User

      • 9.5.13. Rest of LAMEA Disease-modifying Agents Market

        • 9.5.13.1. Market Size and Forecast, By Drug Class
        • 9.5.13.2. Market Size and Forecast, By Indication
        • 9.5.13.3. Market Size and Forecast, By Therapy Type
        • 9.5.13.4. Market Size and Forecast, By Route Of Administration
        • 9.5.13.5. Market Size and Forecast, By End User

  • CHAPTER 10: COMPETITIVE LANDSCAPE

    • 10.1. Introduction

    • 10.2. Top Winning Strategies

    • 10.3. Product Mapping Of Top 10 Player

    • 10.4. Competitive Dashboard

    • 10.5. Competitive Heatmap

    • 10.6. Top Player Positioning, 2024

  • CHAPTER 11: COMPANY PROFILES

    • 11.1. Biogen Inc.

      • 11.1.1. Company Overview

      • 11.1.2. Key Executives

      • 11.1.3. Company Snapshot

      • 11.1.4. Operating Business Segments

      • 11.1.5. Product Portfolio

      • 11.1.6. Business Performance

      • 11.1.7. Key Strategic Moves and Developments

    • 11.2. Merck KGaA

      • 11.2.1. Company Overview

      • 11.2.2. Key Executives

      • 11.2.3. Company Snapshot

      • 11.2.4. Operating Business Segments

      • 11.2.5. Product Portfolio

      • 11.2.6. Business Performance

      • 11.2.7. Key Strategic Moves and Developments

    • 11.3. Elan Pharma India Pvt Ltd.

      • 11.3.1. Company Overview

      • 11.3.2. Key Executives

      • 11.3.3. Company Snapshot

      • 11.3.4. Operating Business Segments

      • 11.3.5. Product Portfolio

      • 11.3.6. Business Performance

      • 11.3.7. Key Strategic Moves and Developments

    • 11.4. Fresenius Kabi

      • 11.4.1. Company Overview

      • 11.4.2. Key Executives

      • 11.4.3. Company Snapshot

      • 11.4.4. Operating Business Segments

      • 11.4.5. Product Portfolio

      • 11.4.6. Business Performance

      • 11.4.7. Key Strategic Moves and Developments

    • 11.5. Pfizer Inc

      • 11.5.1. Company Overview

      • 11.5.2. Key Executives

      • 11.5.3. Company Snapshot

      • 11.5.4. Operating Business Segments

      • 11.5.5. Product Portfolio

      • 11.5.6. Business Performance

      • 11.5.7. Key Strategic Moves and Developments

    • 11.6. Teva Pharmaceutical Industries Ltd.

      • 11.6.1. Company Overview

      • 11.6.2. Key Executives

      • 11.6.3. Company Snapshot

      • 11.6.4. Operating Business Segments

      • 11.6.5. Product Portfolio

      • 11.6.6. Business Performance

      • 11.6.7. Key Strategic Moves and Developments

    • 11.7. Hospira, Inc.

      • 11.7.1. Company Overview

      • 11.7.2. Key Executives

      • 11.7.3. Company Snapshot

      • 11.7.4. Operating Business Segments

      • 11.7.5. Product Portfolio

      • 11.7.6. Business Performance

      • 11.7.7. Key Strategic Moves and Developments

    • 11.8. Accord Healthcare Inc

      • 11.8.1. Company Overview

      • 11.8.2. Key Executives

      • 11.8.3. Company Snapshot

      • 11.8.4. Operating Business Segments

      • 11.8.5. Product Portfolio

      • 11.8.6. Business Performance

      • 11.8.7. Key Strategic Moves and Developments

    • 11.9. Nordic Group Bv

      • 11.9.1. Company Overview

      • 11.9.2. Key Executives

      • 11.9.3. Company Snapshot

      • 11.9.4. Operating Business Segments

      • 11.9.5. Product Portfolio

      • 11.9.6. Business Performance

      • 11.9.7. Key Strategic Moves and Developments

    • 11.10. Antares Pharma, Inc.

      • 11.10.1. Company Overview

      • 11.10.2. Key Executives

      • 11.10.3. Company Snapshot

      • 11.10.4. Operating Business Segments

      • 11.10.5. Product Portfolio

      • 11.10.6. Business Performance

      • 11.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL DISEASE-MODIFYING AGENTS MARKET, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR INTERFERON BETA-1α/β, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR NATALIZUMAB, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR MITOXANTRONE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR GLATIRAMER ACETATE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR FINGOLIMOD, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR DIMETHYL FUMARATE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR OCRELIZUMAB, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR TERIFLUNOMIDE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR CICLOSPORIN, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR CYCLOPHOSPHAMIDE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR HYDROXYCHLOROQUINE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR LEFLUNOMIDE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 14. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR METHOTREXATE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 15. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR MYCOPHENOLATE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 16. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR SULFASALAZINE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 17. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 18. GLOBAL DISEASE-MODIFYING AGENTS MARKET, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 19. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 20. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 21. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR PSORIATIC ARTHRITIS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 22. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR ANKYLOSING SPONDYLITIS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 23. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR SYSTEMIC SCLEROSIS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 24. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR CANCER, BY REGION, 2025-2033 ($MILLION)
  • TABLE 25. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 26. GLOBAL DISEASE-MODIFYING AGENTS MARKET, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 27. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR MONOTHERAPY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 28. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR COMBINATION THERAPY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 29. GLOBAL DISEASE-MODIFYING AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 30. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR ORAL, BY REGION, 2025-2033 ($MILLION)
  • TABLE 31. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR INFUSION, BY REGION, 2025-2033 ($MILLION)
  • TABLE 32. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR SUBCUTANEOUS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 33. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR INTRAVENOUS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 34. GLOBAL DISEASE-MODIFYING AGENTS MARKET, BY END USER, 2025-2033 ($MILLION)
  • TABLE 35. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 36. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR RETAIL PHARMACIES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 37. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR ONLINE PHARMACIES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 38. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 39. GLOBAL DISEASE-MODIFYING AGENTS MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 40. NORTH AMERICA DISEASE-MODIFYING AGENTS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 41. NORTH AMERICA DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 42. NORTH AMERICA DISEASE-MODIFYING AGENTS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 43. NORTH AMERICA DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 44. NORTH AMERICA DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 45. NORTH AMERICA DISEASE-MODIFYING AGENTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 46. U.S. DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 47. U.S. DISEASE-MODIFYING AGENTS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 48. U.S. DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 49. U.S. DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 50. U.S. DISEASE-MODIFYING AGENTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 51. CANADA DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 52. CANADA DISEASE-MODIFYING AGENTS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 53. CANADA DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 54. CANADA DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 55. CANADA DISEASE-MODIFYING AGENTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 56. MEXICO DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 57. MEXICO DISEASE-MODIFYING AGENTS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 58. MEXICO DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 59. MEXICO DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 60. MEXICO DISEASE-MODIFYING AGENTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 61. EUROPE DISEASE-MODIFYING AGENTS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 62. EUROPE DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 63. EUROPE DISEASE-MODIFYING AGENTS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 64. EUROPE DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 65. EUROPE DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 66. EUROPE DISEASE-MODIFYING AGENTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 67. FRANCE DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 68. FRANCE DISEASE-MODIFYING AGENTS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 69. FRANCE DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 70. FRANCE DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 71. FRANCE DISEASE-MODIFYING AGENTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 72. GERMANY DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 73. GERMANY DISEASE-MODIFYING AGENTS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 74. GERMANY DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 75. GERMANY DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 76. GERMANY DISEASE-MODIFYING AGENTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 77. ITALY DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 78. ITALY DISEASE-MODIFYING AGENTS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 79. ITALY DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 80. ITALY DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 81. ITALY DISEASE-MODIFYING AGENTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 82. SPAIN DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 83. SPAIN DISEASE-MODIFYING AGENTS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 84. SPAIN DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 85. SPAIN DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 86. SPAIN DISEASE-MODIFYING AGENTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 87. UK DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 88. UK DISEASE-MODIFYING AGENTS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 89. UK DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 90. UK DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 91. UK DISEASE-MODIFYING AGENTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 92. RUSSIA DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 93. RUSSIA DISEASE-MODIFYING AGENTS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 94. RUSSIA DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 95. RUSSIA DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 96. RUSSIA DISEASE-MODIFYING AGENTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 97. REST OF EUROPE DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 98. REST OF EUROPE DISEASE-MODIFYING AGENTS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 99. REST OF EUROPE DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 100. REST OF EUROPE DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 101. REST OF EUROPE DISEASE-MODIFYING AGENTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 102. ASIA-PACIFIC DISEASE-MODIFYING AGENTS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 103. ASIA-PACIFIC DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 104. ASIA-PACIFIC DISEASE-MODIFYING AGENTS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 105. ASIA-PACIFIC DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 106. ASIA-PACIFIC DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 107. ASIA-PACIFIC DISEASE-MODIFYING AGENTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 108. CHINA DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 109. CHINA DISEASE-MODIFYING AGENTS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 110. CHINA DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 111. CHINA DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 112. CHINA DISEASE-MODIFYING AGENTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 113. JAPAN DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 114. JAPAN DISEASE-MODIFYING AGENTS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 115. JAPAN DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 116. JAPAN DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 117. JAPAN DISEASE-MODIFYING AGENTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 118. INDIA DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 119. INDIA DISEASE-MODIFYING AGENTS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 120. INDIA DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 121. INDIA DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 122. INDIA DISEASE-MODIFYING AGENTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 123. SOUTH KOREA DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 124. SOUTH KOREA DISEASE-MODIFYING AGENTS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 125. SOUTH KOREA DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 126. SOUTH KOREA DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 127. SOUTH KOREA DISEASE-MODIFYING AGENTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 128. AUSTRALIA DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 129. AUSTRALIA DISEASE-MODIFYING AGENTS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 130. AUSTRALIA DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 131. AUSTRALIA DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 132. AUSTRALIA DISEASE-MODIFYING AGENTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 133. THAILAND DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 134. THAILAND DISEASE-MODIFYING AGENTS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 135. THAILAND DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 136. THAILAND DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 137. THAILAND DISEASE-MODIFYING AGENTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 138. MALAYSIA DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 139. MALAYSIA DISEASE-MODIFYING AGENTS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 140. MALAYSIA DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 141. MALAYSIA DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 142. MALAYSIA DISEASE-MODIFYING AGENTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 143. INDONESIA DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 144. INDONESIA DISEASE-MODIFYING AGENTS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 145. INDONESIA DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 146. INDONESIA DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 147. INDONESIA DISEASE-MODIFYING AGENTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 148. REST OF ASIA PACIFIC DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 149. REST OF ASIA PACIFIC DISEASE-MODIFYING AGENTS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 150. REST OF ASIA PACIFIC DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 151. REST OF ASIA PACIFIC DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 152. REST OF ASIA PACIFIC DISEASE-MODIFYING AGENTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 153. LAMEA DISEASE-MODIFYING AGENTS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 154. LAMEA DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 155. LAMEA DISEASE-MODIFYING AGENTS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 156. LAMEA DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 157. LAMEA DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 158. LAMEA DISEASE-MODIFYING AGENTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 159. BRAZIL DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 160. BRAZIL DISEASE-MODIFYING AGENTS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 161. BRAZIL DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 162. BRAZIL DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 163. BRAZIL DISEASE-MODIFYING AGENTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 164. SOUTH AFRICA DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 165. SOUTH AFRICA DISEASE-MODIFYING AGENTS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 166. SOUTH AFRICA DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 167. SOUTH AFRICA DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 168. SOUTH AFRICA DISEASE-MODIFYING AGENTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 169. SAUDI ARABIA DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 170. SAUDI ARABIA DISEASE-MODIFYING AGENTS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 171. SAUDI ARABIA DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 172. SAUDI ARABIA DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 173. SAUDI ARABIA DISEASE-MODIFYING AGENTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 174. UAE DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 175. UAE DISEASE-MODIFYING AGENTS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 176. UAE DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 177. UAE DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 178. UAE DISEASE-MODIFYING AGENTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 179. ARGENTINA DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 180. ARGENTINA DISEASE-MODIFYING AGENTS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 181. ARGENTINA DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 182. ARGENTINA DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 183. ARGENTINA DISEASE-MODIFYING AGENTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 184. REST OF LAMEA DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 185. REST OF LAMEA DISEASE-MODIFYING AGENTS, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 186. REST OF LAMEA DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 187. REST OF LAMEA DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 188. REST OF LAMEA DISEASE-MODIFYING AGENTS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 189. BIOGEN INC.: KEY EXECUTIVES
  • TABLE 190. BIOGEN INC.: COMPANY SNAPSHOT
  • TABLE 191. BIOGEN INC.: OPERATING SEGMENTS
  • TABLE 192. BIOGEN INC.: PRODUCT PORTFOLIO
  • TABLE 193. BIOGEN INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 194. MERCK KGAA: KEY EXECUTIVES
  • TABLE 195. MERCK KGAA: COMPANY SNAPSHOT
  • TABLE 196. MERCK KGAA: OPERATING SEGMENTS
  • TABLE 197. MERCK KGAA: PRODUCT PORTFOLIO
  • TABLE 198. MERCK KGAA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 199. ELAN PHARMA INDIA PVT LTD.: KEY EXECUTIVES
  • TABLE 200. ELAN PHARMA INDIA PVT LTD.: COMPANY SNAPSHOT
  • TABLE 201. ELAN PHARMA INDIA PVT LTD.: OPERATING SEGMENTS
  • TABLE 202. ELAN PHARMA INDIA PVT LTD.: PRODUCT PORTFOLIO
  • TABLE 203. ELAN PHARMA INDIA PVT LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 204. FRESENIUS KABI: KEY EXECUTIVES
  • TABLE 205. FRESENIUS KABI: COMPANY SNAPSHOT
  • TABLE 206. FRESENIUS KABI: OPERATING SEGMENTS
  • TABLE 207. FRESENIUS KABI: PRODUCT PORTFOLIO
  • TABLE 208. FRESENIUS KABI: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 209. PFIZER INC: KEY EXECUTIVES
  • TABLE 210. PFIZER INC: COMPANY SNAPSHOT
  • TABLE 211. PFIZER INC: OPERATING SEGMENTS
  • TABLE 212. PFIZER INC: PRODUCT PORTFOLIO
  • TABLE 213. PFIZER INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 214. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 215. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 216. TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
  • TABLE 217. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 218. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 219. HOSPIRA, INC.: KEY EXECUTIVES
  • TABLE 220. HOSPIRA, INC.: COMPANY SNAPSHOT
  • TABLE 221. HOSPIRA, INC.: OPERATING SEGMENTS
  • TABLE 222. HOSPIRA, INC.: PRODUCT PORTFOLIO
  • TABLE 223. HOSPIRA, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 224. ACCORD HEALTHCARE INC: KEY EXECUTIVES
  • TABLE 225. ACCORD HEALTHCARE INC: COMPANY SNAPSHOT
  • TABLE 226. ACCORD HEALTHCARE INC: OPERATING SEGMENTS
  • TABLE 227. ACCORD HEALTHCARE INC: PRODUCT PORTFOLIO
  • TABLE 228. ACCORD HEALTHCARE INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 229. NORDIC GROUP BV: KEY EXECUTIVES
  • TABLE 230. NORDIC GROUP BV: COMPANY SNAPSHOT
  • TABLE 231. NORDIC GROUP BV: OPERATING SEGMENTS
  • TABLE 232. NORDIC GROUP BV: PRODUCT PORTFOLIO
  • TABLE 233. NORDIC GROUP BV: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 234. ANTARES PHARMA, INC.: KEY EXECUTIVES
  • TABLE 235. ANTARES PHARMA, INC.: COMPANY SNAPSHOT
  • TABLE 236. ANTARES PHARMA, INC.: OPERATING SEGMENTS
  • TABLE 237. ANTARES PHARMA, INC.: PRODUCT PORTFOLIO
  • TABLE 238. ANTARES PHARMA, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL DISEASE-MODIFYING AGENTS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL DISEASE-MODIFYING AGENTS MARKET
  • FIGURE 3. SEGMENTATION DISEASE-MODIFYING AGENTS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN DISEASE-MODIFYING AGENTS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALDISEASE-MODIFYING AGENTS MARKET
  • FIGURE 11. DISEASE-MODIFYING AGENTS MARKET SEGMENTATION, BY BY DRUG CLASS
  • FIGURE 12. DISEASE-MODIFYING AGENTS MARKET FOR INTERFERON BETA-1α/β, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. DISEASE-MODIFYING AGENTS MARKET FOR NATALIZUMAB, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. DISEASE-MODIFYING AGENTS MARKET FOR MITOXANTRONE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. DISEASE-MODIFYING AGENTS MARKET FOR GLATIRAMER ACETATE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. DISEASE-MODIFYING AGENTS MARKET FOR FINGOLIMOD, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. DISEASE-MODIFYING AGENTS MARKET FOR DIMETHYL FUMARATE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. DISEASE-MODIFYING AGENTS MARKET FOR OCRELIZUMAB, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. DISEASE-MODIFYING AGENTS MARKET FOR TERIFLUNOMIDE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. DISEASE-MODIFYING AGENTS MARKET FOR CICLOSPORIN, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. DISEASE-MODIFYING AGENTS MARKET FOR CYCLOPHOSPHAMIDE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 22. DISEASE-MODIFYING AGENTS MARKET FOR HYDROXYCHLOROQUINE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 23. DISEASE-MODIFYING AGENTS MARKET FOR LEFLUNOMIDE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 24. DISEASE-MODIFYING AGENTS MARKET FOR METHOTREXATE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 25. DISEASE-MODIFYING AGENTS MARKET FOR MYCOPHENOLATE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 26. DISEASE-MODIFYING AGENTS MARKET FOR SULFASALAZINE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 27. DISEASE-MODIFYING AGENTS MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 28. DISEASE-MODIFYING AGENTS MARKET SEGMENTATION, BY BY INDICATION
  • FIGURE 29. DISEASE-MODIFYING AGENTS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 30. DISEASE-MODIFYING AGENTS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 31. DISEASE-MODIFYING AGENTS MARKET FOR PSORIATIC ARTHRITIS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 32. DISEASE-MODIFYING AGENTS MARKET FOR ANKYLOSING SPONDYLITIS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 33. DISEASE-MODIFYING AGENTS MARKET FOR SYSTEMIC SCLEROSIS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 34. DISEASE-MODIFYING AGENTS MARKET FOR CANCER, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 35. DISEASE-MODIFYING AGENTS MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 36. DISEASE-MODIFYING AGENTS MARKET SEGMENTATION, BY BY THERAPY TYPE
  • FIGURE 37. DISEASE-MODIFYING AGENTS MARKET FOR MONOTHERAPY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 38. DISEASE-MODIFYING AGENTS MARKET FOR COMBINATION THERAPY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 39. DISEASE-MODIFYING AGENTS MARKET SEGMENTATION, BY BY ROUTE OF ADMINISTRATION
  • FIGURE 40. DISEASE-MODIFYING AGENTS MARKET FOR ORAL, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 41. DISEASE-MODIFYING AGENTS MARKET FOR INFUSION, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 42. DISEASE-MODIFYING AGENTS MARKET FOR SUBCUTANEOUS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 43. DISEASE-MODIFYING AGENTS MARKET FOR INTRAVENOUS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 44. DISEASE-MODIFYING AGENTS MARKET SEGMENTATION, BY BY END USER
  • FIGURE 45. DISEASE-MODIFYING AGENTS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 46. DISEASE-MODIFYING AGENTS MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 47. DISEASE-MODIFYING AGENTS MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 48. DISEASE-MODIFYING AGENTS MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 49. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 50. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 51. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 52. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 53. COMPETITIVE DASHBOARD
  • FIGURE 54. COMPETITIVE HEATMAP: DISEASE-MODIFYING AGENTS MARKET
  • FIGURE 55. TOP PLAYER POSITIONING, 2024
  • FIGURE 56. BIOGEN INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 57. BIOGEN INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 58. BIOGEN INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 59. MERCK KGAA: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 60. MERCK KGAA: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 61. MERCK KGAA: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 62. ELAN PHARMA INDIA PVT LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 63. ELAN PHARMA INDIA PVT LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 64. ELAN PHARMA INDIA PVT LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 65. FRESENIUS KABI: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 66. FRESENIUS KABI: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 67. FRESENIUS KABI: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 68. PFIZER INC: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 69. PFIZER INC: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 70. PFIZER INC: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 71. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 72. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 73. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 74. HOSPIRA, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 75. HOSPIRA, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 76. HOSPIRA, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 77. ACCORD HEALTHCARE INC: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 78. ACCORD HEALTHCARE INC: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 79. ACCORD HEALTHCARE INC: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 80. NORDIC GROUP BV: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 81. NORDIC GROUP BV: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 82. NORDIC GROUP BV: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 83. ANTARES PHARMA, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 84. ANTARES PHARMA, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 85. ANTARES PHARMA, INC.: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Disease-Modifying Agents Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved